Lineage Cell Therapeutics
LCTX
LCTX
76 hedge funds and large institutions have $49.8M invested in Lineage Cell Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
19% less funds holding
Funds holding: 94 → 76 (-18)
46% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 24
90% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 20
Holders
76
Holding in Top 10
3
Calls
$67K
Puts
$1K
Top Buyers
| 1 | +$377K | |
| 2 | +$118K | |
| 3 | +$86K | |
| 4 |
Two Sigma Advisers
New York
|
+$43K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$24.3K |
Top Sellers
| 1 | -$761K | |
| 2 | -$665K | |
| 3 | -$284K | |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$219K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$142K |